New Publications
How to use biosimilars and generic NBCDs as MS DMTs?
just published and co-authored by Dr Wolf:
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendation.
[...]
Phase II for a 2nd-generation DHDOH inhibitor
just published and co-authored by Dr Wolf:
A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.
[...]
A Continued Role for Glatiramer Acetate?
just published and co-authored by Dr Wolf:
Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
[...]
Landmark clinical equivalence study in MS
just published and co-authored by Dr Wolf:
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. A Randomized Clinical Trial.
[...]
Patient-volunteer studies in Multiple Sclerosis
just published and co-authored by Dr Wolf:
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study.
Long-Term Disability in Multiple Sclerosis
just published and co-authored by Dr Wolf:
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
Patient-volunteer studies in Multiple Sclerosis
just published and co-authored by Dr Wolf:
Benefits of a Single Versus Multicenter Approach in Early-Phase Patient Studies. A Case Study of Multiple Sclerosis Patients.
[...]CSF and Blood Biobanking
just published and co-authored by Dr Wolf:
Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.
[...]